142 related articles for article (PubMed ID: 32527713)
21. Silybin B and Cianidanol Inhibit M
Srivastava R; Tripathi S; Unni S; Hussain A; Haque S; Dasgupta N; Singh V; Mishra BN
Curr Pharm Des; 2021; 27(32):3476-3489. PubMed ID: 33302853
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Some Antiviral Natural Products to Fight Against Novel Coronavirus (SARS-CoV-2) Using an
Shah A; Patel V; Parmar B
Comb Chem High Throughput Screen; 2021; 24(8):1271-1280. PubMed ID: 32881661
[TBL] [Abstract][Full Text] [Related]
23. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation.
Gorla US; Rao K; Kulandaivelu US; Alavala RR; Panda SP
Comb Chem High Throughput Screen; 2021; 24(6):879-890. PubMed ID: 32819226
[TBL] [Abstract][Full Text] [Related]
24. Development and Evaluation of Peptidomimetic Compounds against SARS-CoV-2 Spike Protein: An in silico and in vitro Study.
Zarei O; Kleine-Weber H; Hoffmann M; Hamzeh-Mivehroud M
Mol Inform; 2022 Jul; 41(7):e2100231. PubMed ID: 35068079
[TBL] [Abstract][Full Text] [Related]
25.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of a Siddha Medicine fixed regimen for the treatment of asymptomatic and mild COVID-19 patients.
Kannan M; Sathiyarajeswaran P; Sasikumar D; Geetha A; Mohanapriya M; Vinod NP; Manickam P; Kanakavalli K; Parthibhan P; Pitchiah Kumar M; Kannan R; Sivaraman G
J Ayurveda Integr Med; 2022; 13(3):100589. PubMed ID: 35634543
[TBL] [Abstract][Full Text] [Related]
27.
Rout J; Swain BC; Tripathy U
J Biomol Struct Dyn; 2022 Feb; 40(2):860-874. PubMed ID: 32938313
[TBL] [Abstract][Full Text] [Related]
28. In Silico Studies Reveal Antiviral Effects of Traditional Indian Spices on COVID-19.
Kumar B; Zaidi S; Haque S; Dasgupta N; Hussain A; Pramodh S; Singh V; Mishra BN
Curr Pharm Des; 2021; 27(32):3462-3475. PubMed ID: 33357192
[TBL] [Abstract][Full Text] [Related]
29. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
Maurya SK; Maurya AK; Mishra N; Siddique HR
J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594
[TBL] [Abstract][Full Text] [Related]
30. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
31. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
[TBL] [Abstract][Full Text] [Related]
32. Phytochemicals as potential drug candidates for targeting SARS CoV 2 proteins, an in silico study.
Nag A; Banerjee R; Chowdhury RR; Krishnapura Venkatesh C
Virusdisease; 2021 Mar; 32(1):98-107. PubMed ID: 33842673
[TBL] [Abstract][Full Text] [Related]
33. An open clinical evaluation of selected siddha regimen in expediting the management of COVID-19 -a randomized controlled study.
Chitra SM; Mallika P; Anbu N; Narayanababu R; Sugunabai A; David Paul Raj RS; Premnath D
J Ayurveda Integr Med; 2022; 13(1):100397. PubMed ID: 33519133
[TBL] [Abstract][Full Text] [Related]
34. Molecular Docking Studies to Identify Promising Natural Inhibitors Targeting SARS-CoV-2 Nsp10-Nsp16 Protein Complex.
Bhardwaj A; Sharma S; Singh SK
Turk J Pharm Sci; 2022 Feb; 19(1):93-100. PubMed ID: 35227055
[TBL] [Abstract][Full Text] [Related]
35. Potential Inhibitors of SARS-CoV-2 from
Yusuf AJ; Abdullahi MI; Musa AM; Abubakar H; Amali AM; Nasir AH
Turk J Pharm Sci; 2022 Apr; 19(2):202-212. PubMed ID: 35510348
[TBL] [Abstract][Full Text] [Related]
36. Determination of inhibitor activity of drugs against the COVID-19.
Gedikli MA; Tuzun B; Sayin K; Ataseven H
Bratisl Lek Listy; 2021; 122(7):497-506. PubMed ID: 34161118
[TBL] [Abstract][Full Text] [Related]
37. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
38. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of SARS-CoV2 viral infection with natural antiviral plants constituents: An in-silico approach.
Das K; Das P; Almuqbil M; Asdaq SMB; Nikhil K; Preethi K; Angelinkiruba A; Alomar NF; Al Harbi RM; Al Abdullah WA; Alshehri SM; Laghabi YA; Alsaegh AR; Mohzari Y; Alshehri S; Mannasaheb BA; Rabbani SI
J King Saud Univ Sci; 2023 Apr; 35(3):102534. PubMed ID: 36619666
[TBL] [Abstract][Full Text] [Related]
40.
Ram TS; Munikumar M; Raju VN; Devaraj P; Boiroju NK; Hemalatha R; Prasad PVV; Gundeti M; Sisodia BS; Pawar S; Prasad GP; Chincholikar M; Goel S; Mangal A; Gaidhani S; Srikanth N; Dhiman KS
J Ayurveda Integr Med; 2022; 13(1):100413. PubMed ID: 33654345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
